References
- Jemal A., Thomas A., Murray T., Thun M. Cancer statistics. CA Cancer J. Clin. 2002; 52(1)23–47, [PUBMED], [INFOTRIEVE], [CSA]
- Ahlgren J. D. Chemotherapy for pancreatic carcinoma. Cancer 1996; 78(3 suppl)654–663, [PUBMED], [INFOTRIEVE]
- Burris H. A., III, Moore M. J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997; 15: 2403–2413, [PUBMED], [INFOTRIEVE]
- Carmichael J., Fink U., Russell R. C., et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 1996; 73: 101–105, [PUBMED], [INFOTRIEVE]
- Rothenberg M. L., Moore M. J., Cripps M. C., et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol. 1996; 7: 347–353, [PUBMED], [INFOTRIEVE]
- Bissery M. C., Guénard D., Guéritte-Voegelein F., Lavelle F. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991; 51: 4845–4852, [PUBMED], [INFOTRIEVE]
- Abbruzzese J. L., Evans D., Gravel D., et al. Docetaxel (D): a potentially active agent for patients with pancreatic adenocarcinomas (PA). Proc. - Am. Soc. Clin. Oncol. 1995; 14: 221, (abstract 561)
- Preusser P., Niederle N., Harstrick A., et al. Phase II study of docetaxel as first-line chemotherapy in metastatic adenocarcinoma of the pancreas. Proc. Am. Soc. Clin. Oncol. 1999; 18: 297, (abstract 1142)
- Rougier P., Adenis A., Ducreux M., et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur. J. Cancer 2000; 36: 1016–1025, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Androulakis N., Kourousis C., Dimopoulos M. A., et al. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J. Clin. Oncol. 1999; 17: 1779–1785, [PUBMED], [INFOTRIEVE]
- Spiridonidis C. H., Laufman L. R., Jones J., Rhodes V. A., Wallace K., Nicol S. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J. Clin. Oncol. 1998; 16: 3866–3873, [PUBMED], [INFOTRIEVE]
- Choi C. W., Choi I. K., Seo J. H., et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am. J. Clin. Oncol. 2000; 23: 425–428, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lutz M. P., Koniger M., Muche R., et al. A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer. Z. Gastroenterol. 1999; 37: 993–997, [PUBMED], [INFOTRIEVE]
- Rubin J., Gallagher J. G., Schroeder G., et al. Phase II trial of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer 1996; 78: 1888–1891, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Weinerman B. H., MacCormick R. E. A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population. Am. J. Clin. Oncol. 1994; 17: 467–469, [PUBMED], [INFOTRIEVE], [CSA]
- DeCaprio J. A., Mayer R. J., Gonin R., Arbuck S. G. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J. Clin. Oncol. 1991; 9: 2128–2133, [PUBMED], [INFOTRIEVE]
- Tajiri H., Yoshimori M., Okazaki N., Miyaji M. Phase II study of continuous venous infusion of 5-fluorouracil in advanced pancreatic cancer. Oncology 1991; 48: 18–21, [PUBMED], [INFOTRIEVE]
- Crown J., Casper E. S., Botet J., Murray P., Kelsen D. P. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J. Clin. Oncol. 1991; 9: 1682–1686, [PUBMED], [INFOTRIEVE]
- Hansen R., Quebbeman E., Ritch P., Chitambar C., Anderson T. Continuous 5-fluorouracil (5-FU) infusion in carcinoma of the pancreas: a phase II study. Am. J. Med. Sci. 1988; 295: 91–93, [PUBMED], [INFOTRIEVE]
- Crinò L., Mosconi A. M., Calandri C., et al. Gemcitabine in advanced pancreatic cancer: a phase II trial. Am. J. Clin. Oncol. 2001; 24: 296–298, [CROSSREF], [CSA]
- Ulrich-Pur H., Kornek G. V., Raderer M., et al. A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma. Cancer 2000; 88: 2505–2511, [CROSSREF]
- Casper E. S., Green M. R., Kelsen D. P., et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs 1994; 12: 29–34, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Klein B., Sadikov E., Mishaeli M., Levin I., Figer A. Comparison of 5-FU and leucovorin to gemcitabine in the treatment of pancreatic cancer. Oncol. Rep. 2000; 7: 875–877, [PUBMED], [INFOTRIEVE], [CSA]
- Okada S., Sakata Y., Matsuno S., et al. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Br. J. Cancer 1999; 80: 438–443, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Cascinu S., Gasparini G., Catalano V., et al. A phase I–II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann. Oncol. 1999; 10: 1377–1379, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sherman W. H., Fine R. L. Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology 2001; 60: 316–321, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Stathopoulos G. P., Mavroudis D., Tsavaris N., et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann. Oncol. 2001; 12: 101–103, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Marruchella A., Fiorenzano G., Merizzi A., Rossi G., Chiodera P. L. Diffuse alveolar damage in a patient treated with gemcitabine. Eur. Respir. J. 1998; 11: 504–506, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Pavlakis N., Bell D. R., Millward M. J., Levi J. A. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286–291, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gupta N., Imran A., Steinberg H., Patel D., Nissel-Horowitz S., Mehrotra B. Gemcitabine-induced pulmonary toxicity. Case report and review of the literature. Am. J. Clin. Oncol. (CCT) 2002; 25(1)96–100, [CROSSREF]
- Sauer-Heilborn A., Kath R., Schneider C. P., Höffken K. Severe non-haematological toxicity after treatment with gemcitabine. J. Cancer Res. Clin. Oncol. 1999; 125: 637–640, [CROSSREF], [CSA]
- Read W. L., Mortimer J. E., Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002; 94: 843–847, [CROSSREF]
- Merad M., Le Cesne A., Baldeyrou P., Mesurolle B., Le Chevalier T. Docetaxel and interstitial pulmonary injury. Ann. Oncol. 1997; 8: 191–194, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Dunsford M. L., Mead G. M., Bateman A. C., Cook T., Tung K. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann. Oncol. 1999; 10: 943–947, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kulke M. H., Niedzwiecki D., Tempero M. A., Hollis D. R., Mayer R. J. A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed-dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904). Proc. Am. Soc. Clin. Oncol. 2004; 22: 4011
- Philip P. A., Zalupski M. M., Zaitkevicius V. K., et al. Phase II study of gemcitabine and cisplatin in the treatment of advanced pancreatic cancer. Cancer 2001; 92(3)569–577, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Rocha Lima C. M.S., Savarese D., Bruckner H., et al. Irinotecan plus gemcitabine induces both radiographic and CA19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J. Clin. Oncol. 2002; 20: 1182–1191, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Berlin J. D., Catalano P., Thomas J. P., Kugler J. W., Haller D. G., Benson A. B., III. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 2002; 20: 3270–3275, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Abbruzzese J. L., Rosenberg A., Xiong Q., et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody Cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer (abstract). Proc. Ann. Soc. Clin. Oncol. 2001; 20: A518